Etretinate

CHEMBL464 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

354.5 g/mol

LogP

6.8

Phase

4

This retinoid medication normalizes the growth and shedding of skin cells and was used to treat severe, treatment-resistant psoriasis. It has been withdrawn from most markets due to its long persistence in the body and severe risk of birth defects.

분자량

354.5000 g/mol

LogP

6.80

TPSA

35.50 Å²

리핀스키 5의 법칙

통과

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C

InChI

InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+

Molecular Formula

C23H30O3

HBD / HBA

- / 3

회전 가능 결합

8

무거운 원자

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This retinoid medication normalizes the growth and shedding of skin cells and was used to treat severe, treatment-resistant psoriasis. It has been withdrawn from most markets due to its long persistence in the body and severe risk of birth defects.

Yes, Etretinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL464. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5282375. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Etretinate PillFYI에서

구조

핵심 데이터

분자식: C23H30O3

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.